Diabetes Mellitus / Steroid-Induced Hyperglycemia Secondary to Inflammatory or Autoimmune Condition (Treated with Corticosteroids)

Yes. Under 38 CFR § 3.310(a), any disability proximately caused or chronically worsened by a service-connected condition is itself service-connected. Diabetes Mellitus / Steroid-Induced Hyperglycemia is a documented secondary pairing for Inflammatory or Autoimmune Condition (Treated with Corticosteroids) with strong medical evidence. A nexus letter from a qualified physician linking the two conditions is the most reliable way to establish this connection.

The gold standard is a private nexus opinion stating — to at least a 50% probability ("at least as likely as not") — that the secondary condition was caused or aggravated by the primary service-connected condition. Peer-reviewed medical literature supporting the physiological mechanism strengthens the nexus. Treatment records documenting the onset or worsening of the secondary condition in temporal relation to the primary are supporting evidence.

The VA rates Diabetes Mellitus / Steroid-Induced Hyperglycemia separately under its own 38 CFR Part 4 diagnostic code, then combines it with Inflammatory or Autoimmune Condition (Treated with Corticosteroids) and all other service-connected ratings using the combined ratings formula under § 4.25. The formula applies the whole-person concept: a 50% combined existing rating plus a new 30% rating yields 65% (rounded to 70%), not 80%.

38 CFR § 3.310(a) states: "Disability which is proximately due to or the result of a service-connected disease or injury shall be service connected." The aggravation variant under § 3.310(b) applies where the primary condition permanently worsens a pre-existing disability beyond its natural progression. Both standards require a showing of nexus — a medical or scientific link between the primary condition and the secondary.

The medical evidence supporting Diabetes Mellitus / Steroid-Induced Hyperglycemia as secondary to Inflammatory or Autoimmune Condition (Treated with Corticosteroids) is rated strong. Systemic corticosteroid therapy (prednisone, methylprednisolone, dexamethasone, hydrocortisone) prescribed for service-connected inflammatory or autoimmune conditions causes iatrogenic diabetes mellitus through well-characterized mechanisms. Glucocorticoids induce peripheral insulin resistance by: (1) suppressing GLUT4 glucose transporter translocation in skeletal muscle; (2) increasing hepatic gluconeogenesis by activating key gluconeogenic enzymes (PEPCK, glucose-6-phosphatase); (3) directly inhibiting insulin secretion from pancreatic beta-cells at high doses; and (4) promoting lipolysis with increased free fatty acid delivery to the liver, driving de novo lipogenesis and hepatic glucose output. Studies of patients on systemic corticosteroid therapy document new-onset hyperglycemia in 30–50%, with frank diabetes mellitus in 5–20% depending on dose, duration, and baseline metabolic risk. Steroid-induced diabetes persists after steroid discontinuation in a significant minority of patients.

The VA will not solicit nexus evidence on your behalf for secondary claims. In practice, a written nexus opinion from a private physician or independent medical examiner is essential — the VA's Compensation & Pension (C&P) examiner is not required to produce a favorable nexus opinion, and the VA has discretion to weigh competing opinions. Submitting a private nexus letter at the time of filing is the most reliable strategy.